

# UC Berkeley

## UC Berkeley Previously Published Works

### Title

Regulatory control circuits for stabilizing long-term anabolic product formation in yeast

### Permalink

<https://escholarship.org/uc/item/0cg460bm>

### Authors

D'Ambrosio, Vasil

Dore, Eleonora

Di Blasi, Roberto

et al.

### Publication Date

2020-09-01

### DOI

10.1016/j.ymben.2020.07.006

Peer reviewed

# 1 **Regulatory control circuits for stabilizing long-term anabolic product formation in yeast**

2

3 Vasil D'Ambrosio<sup>1#</sup>, Eleonora Dore<sup>1#</sup>, Roberto Di Blasi<sup>1</sup>, Marcel van den Broek<sup>2</sup>, Suresh Sudarsan<sup>1</sup>,  
4 Jolanda ter Horst<sup>1</sup>, Francesca Ambri<sup>1</sup>, Morten O.A. Sommer<sup>1</sup>, Peter Rugbjerg<sup>1</sup>, Jay. D Keasling<sup>1,3-6</sup>,  
5 Robert Mans<sup>2\*</sup>, and Michael K. Jensen<sup>1\*</sup>

6

7 <sup>1</sup> Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kgs.  
8 Lyngby, Denmark

9 <sup>2</sup> Department of Biotechnology, Delft University of Technology, Delft, The Netherlands

10 <sup>3</sup> Joint BioEnergy Institute, Emeryville, CA, USA

11 <sup>4</sup> Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley,  
12 CA, USA

13 <sup>5</sup> Department of Chemical and Biomolecular Engineering, Department of Bioengineering, University  
14 of California,  
15 Berkeley, CA, USA

16 <sup>6</sup> Center for Synthetic Biochemistry, Institute for Synthetic Biology, Shenzhen Institutes of Advanced  
17 Technologies,  
18 Shenzhen, China

19

20 \* To whom correspondence should be addressed. Michael K. Jensen, Email: [mije@biosustain.dtu.dk](mailto:mije@biosustain.dtu.dk)  
21 & Robert Mans, Email: [R.Mans@tudelft.nl](mailto:R.Mans@tudelft.nl),

22 # These authors contributed equally to this study

23

## 24 **Abstract**

25

26 Engineering living cells for production of chemicals, enzymes and therapeutics can burden  
27 cells due to use of limited native co-factor availability and/or expression burdens, totalling a fitness  
28 deficit compared to parental cells encoded through long evolutionary trajectories to maximise fitness.  
29 Ultimately, this discrepancy puts a selective pressure against fitness-burdened engineered cells under  
30 prolonged bioprocesses, and potentially leads to complete eradication of high-performing engineered  
31 cells at the population level. Here we present the mutation landscapes of fitness-burdened yeast cells  
32 engineered for vanillin- $\beta$ -glucoside production. Next, we design synthetic control circuits based on

33 transcriptome analysis and biosensors responsive to vanillin- $\beta$ -glucoside pathway intermediates in  
34 order to stabilize vanillin- $\beta$ -glucoside production over ~55 generations in sequential passage  
35 experiments. Furthermore, using biosensors with two different modes of action we identify control  
36 circuits linking vanillin- $\beta$ -glucoside pathway flux to various essential cellular functions, and  
37 demonstrate control circuits robustness and almost 2-fold higher vanillin- $\beta$ -glucoside production,  
38 including 5-fold increase in total vanillin- $\beta$ -glucoside pathway metabolite accumulation, in a fed-  
39 batch fermentation compared to vanillin- $\beta$ -glucoside producing cells without control circuits.

40

## 41 **Introduction**

42

43 To support sustainable and environmentally friendly production-processes, research focuses  
44 on the production of bio-based alternatives to petroleum-based production processes, made by  
45 engineered cell factories (Kruyer and Peralta-Yahya, 2017). However, in order to design  
46 commercially attractive bioprocesses for converting cheap renewable substrates into value-added  
47 chemicals, innovative bioprocesses need to be developed. For this purpose, online monitoring and  
48 sampling is essential in modern fermentation processes, in order to control and optimize bioreactor  
49 conditions for biobased production (Gomes et al., 2018). Usual parameters analysed online include  
50 pH, exhaust CO<sub>2</sub>, temperature, aeration, agitation, and dissolved oxygen. However, most often, any  
51 of these parameters are mere proxies for evaluating the actual biocatalysis, i.e. the microbial  
52 production of a chemical or protein of interest, which is often analysed offline during or following  
53 completion of the actual fermentation (Gomes et al., 2018).

54 The lack of monitoring and control of culture performance becomes critical as bioreactor  
55 volume and bioprocess duration increase. This is because biobased production over prolonged  
56 cultivation regimes is especially challenged by culture take-over by mutated, low-performing cells  
57 with increased specific growth rates (Rugbjerg and Sommer, 2019; Wang and Dunlop, 2019; Xiao et  
58 al., 2016). Indeed, nongenetic and genetic heterogeneity of microbial populations is largely  
59 acknowledged as evident from large differences in growth rate, resistance to stress, and regulatory  
60 circuit output of isogenic populations (Carlquist et al., 2012; Müller et al., 2010; Rugbjerg et al.,  
61 2018b). Even more so, in industrial high-cell density fed-batch bioprocesses, subpopulations exist  
62 that are many-fold different in these parameters from the population average (Wang and Dunlop,  
63 2019; Xiao et al., 2016). These random variations arise because not all cells are exactly of the same  
64 size, some cells may have been mutated during prolonged seed trains and growth in large-scale

65 cultivations, and nor do all cells have the same number of key components, incl., RNA polymerase,  
66 ribosomes, and other key factors governing the life of a cell (Elowitz et al., 2002; Müller et al., 2010;  
67 Rugbjerg et al., 2018b). In fact, such random variations and evolutionary drifting can give rise to low-  
68 performing variants accounting for up to 80-90% of the total cell population, and produce less than  
69 half of the desired product (Xiao et al., 2016). Thus, there is a strong motivation for developing new  
70 technologies that can monitor biocatalysis, and optimize bioprocesses by coupling detectable  
71 phenotypes to product formation in an efficient manner.

72 Small-molecule biosensors offer sensitive and real-time monitoring of product formation in  
73 microbial cell factories (David et al., 2016; Tao et al., 2017; Zhang et al., 2016), and are furthermore  
74 emerging as a promising technology for safeguarding high-performing productive cell factories from  
75 evolutionary drifting into low-performing ensembles during prolonged cultivations, as those often  
76 applied in industry (Rugbjerg et al., 2018b). Specifically, biosensors based on allosterically regulated  
77 bacterial transcription factors undergo conformational changes upon binding of specific intracellular  
78 ligands, and can directly couple single-cell ligand accumulation to a change in reporter gene  
79 expression (e.g. fluorescence or antibiotic resistance)(Fernandez-López et al. 2015). Biosensors  
80 detecting small-molecule accumulation can be employed for facile evaluation of subpopulation  
81 heterogeneity in diverse feedstock and bioreactor environments, and can support the prototyping of  
82 optimal bioreactor conditions in relation to production of any candidate chemical for which a  
83 biosensor is available (Flachbart et al., 2019; Snoek et al., 2018; Xiao et al., 2016). Also, as the  
84 biosensors can couple product accumulation with gene expression output, they not only allow for  
85 monitoring of product accumulation at the single-cell level (diagnosis), but have also been used to  
86 couple product accumulation to growth of bacterial cell factories, and thereby enable selective growth  
87 advantage of high-performing subpopulation variants and/or shunting of competing metabolic  
88 pathway reactions (therapy)(Rugbjerg et al., 2018b; Xiao et al., 2016).

89 In this study, we evaluate the coupling of fitness-burdening product-formation to biosensor-  
90 controlled expression of essential genes covering four different metabolic functions of baker's yeast  
91 *Saccharomyces cerevisiae* engineered for production of industrially-relevant vanillin- $\beta$ -glucoside.  
92 From this we demonstrate that yeast cells engineered with control circuits based on biosensors  
93 controlling essential gene expression are recalcitrant to evolutionary drifting over 50 generations.  
94 Ultimately, the best-performing control circuit is benchmarked with the parental vanillin- $\beta$ -glucoside  
95 producing strain in a fed-batch fermentation, in which strains with control circuits accumulate 5-fold

96 higher total pathway intermediates, including approximately 2-fold higher final vanillin- $\beta$ -glucoside  
97 levels, compared to the parental strain.

98

## 99 **Results**

100

### 101 **Selection and physiological characterization of production strain**

102 To investigate the ability of genetically-encoded biosensors to stabilize production of ATP-  
103 requiring molecules in yeast, first a proof-of-concept production testbed was selected. Here we chose  
104 a *S. cerevisiae* cell factory engineered for the production of vanillin- $\beta$ -glucoside (VG)(Strucko et al.,  
105 2015). Importantly, vanillin is the main molecule responsible for the vanilla flavour, and one of the  
106 most common nutraceutical compounds, used in food, pharmaceutical cosmetic, and other industries  
107 (Luziatelli et al., 2019) yet yeast strains carrying the vanillin- $\beta$ -glucoside biosynthetic pathway have  
108 been shown to exhibit a reduced growth rate compared to non-producing *S. cerevisiae*  
109 (Supplementary Figure S1)(Brochado et al., 2010; Hansen et al., 2009; Strucko et al., 2017, 2015).  
110 As for biosensors, we sought to employ two recently developed biosensors for VG pathway  
111 intermediates, namely PcaQ from *Sinorhizobium meliloti* for protocatechuic acid (PAC) detection,  
112 and VanR from *Caulobacter crescentus* for vanillic acid (VAC) detection (Ambri et al., 2020).

113 The VG producing strain used in this study carries single-copy genomic integration of five  
114 heterologous genes required for the de novo biosynthesis of vanillin- $\beta$ -glucoside in *S. cerevisiae*: 3-  
115 dehydroshikimate dehydratase (3DSD) from *Podospora anserina*, O-methyltransferase (OMT),  
116 aromatic carboxylic acid reductase (ACAR) from *Nocardia iowensis*, phosphopantetheine transferase  
117 (EntD) from *Escherichia coli* and UDP-glycosyltransferase (UGT) from *Arabidopsis thaliana*  
118 (Brochado et al., 2010; Hansen et al., 2009). Furthermore, the alcohol dehydrogenase *ADH6* and the  
119  $\beta$ -glucosidase *BGL1* genes were removed to further optimise the pathway (Hansen et al., 2009). The  
120 first step converts the native shikimate pathway intermediate 3-dihydroshikimate (3-DHS) to PAC,  
121 which is then converted to vanillin (VAN) through the heterologous intermediates VAC and  
122 protocatechuic aldehyde (PAL). Vanillin is finally converted to vanillin- $\beta$ -glucoside to alleviate  
123 vanillin toxicity and improve product secretion (Brochado et al., 2010; Hansen et al., 2009; Strucko  
124 et al., 2015) (Figure 1A-B).

125 In order to identify potential evolutionary pressure points for genetic instability of strains  
126 expressing the fitness-burdening VG pathway, we constructed single knockout variants of each of the  
127 five genes encoding the VG pathway enzymes, and tested the specific growth rates on synthetic

128 medium permissive for VG formation of all resulting mutant strains compared to the parental VG  
129 producing strain with all five genes left intact (Figure 1C, Supplementary Figure S2). From this  
130 analysis we found that deletion of the *3DSD* gene (VG-3DSD $\Delta$ ), encoding the enzyme catalysing the  
131 conversion from 3DHS to PAC, resulted in increased maximum specific growth rate and shortened  
132 lag phase compared to the full VG pathway strain, whereas deletion of any of the other genes in the  
133 pathway resulted in mutants with reduced growth rates compared to the parental VG pathway strain  
134 (Figure 1C-D). Furthermore, even though the growth rate noticeable differs only between the VG-  
135 3DSD $\Delta$  and VG pathway strain, we observed that when *ACAR*, *hsOMT* or *EntD* genes are deleted,  
136 the lag phase is significantly longer, suggesting that the introduction of the pathway redirects the flux  
137 of metabolites from the biosynthesis of aromatic amino acids to the pathway causing a delay in the  
138 exponential growth phase.

139 Combined, these results indicate that depletion of shikimate intermediates and/or build-up of  
140 VG pathway intermediate PAC impose a fitness burden to the cells, whereas the single loss-of-  
141 function of any other pathway gene results in growth disadvantage, corroborating earlier reports on  
142 vanillin toxicity and the response of *S. cerevisiae* to weak acids and lignin derivatives (Gu et al.,  
143 2019; Guo and Olsson, 2014; Hansen et al., 2009).

144

#### 145 **Assessment of cell factory stability**

146 Having evaluated the burden of the VG pathway on host fitness based on systematic pathway  
147 truncations, we next sought to investigate VG pathway metabolite profiles and pathway stability of  
148 the VG production strain. For this purpose, a serial passaging experiment consisting of seven  
149 sequential transfers (~55 generations) was performed. Here cultures were initially grown in YPD  
150 medium and then transferred in synthetic medium (SM) (Verduyn et al., 1992) to acclimate them to  
151 the experimental conditions (Figure 2A). From this experiment we initially observed that following  
152 first transfer, in which cultures were diluted 1:100 and grown for 48 hours in fresh medium, the  
153 extracellular metabolite content was biased towards PAC, being the first intermediate of the VG  
154 pathway, accumulating to approx. 2 mM, while end-product VG accumulated to 0.78 mM (Figure  
155 2B). This observation agrees with the original VG pathway study performed on this strain (Strucko  
156 et al., 2015). For each of the following transfers, cultures were further diluted 1:100 every 48 hours  
157 into fresh medium, thus initiating the next batch phase (Figure 2A). At the end of each transfer,  
158 samples were collected for quantification of all pathway intermediates and VG end-product formation  
159 in order to assess the total flux through the VG pathway in each batch phase of the passage regime.

160 Following the second transfer, a 46% drop in PAC productivity was observed compared to transfer  
161 1. This result is in line with the sequencing of the *3DSD* gene from seven single colonies from this  
162 transfer where 4 out of 7 sequences were mutated (Supplementary Table S4). ultimately resulting in  
163 the inability to detect any extracellular PAC by the end of the fourth transfer. Similarly, VAC  
164 decreased by 60% and 97% by the end of the second and fourth transfer, respectively (Figure 2C).  
165 On the other hand, the decrease in VAN and VG concentrations was delayed compared to the other  
166 pathway intermediates. In the second transfer the extracellular concentration of VAN and VG only  
167 decreased by 24% and 6%, respectively. However, by the end of the fourth transfer VAN and VG  
168 concentrations decreased by 81.5 and 91.4%, respectively (Figure 2C), whereas by the end of the  
169 experiment VG had decreased by 98.5%.

170 Additionally, at the end of each sequential cultivation, part of the cultivation was stored and  
171 then proceeded we to evaluate the difference in growth between each transfer. Interestingly, we  
172 observed that while the productivity decreased there was a marked increase in growth rate, suggesting  
173 that the mutated strains were overtaking the cultivation (Supplementary Figure S3).

174 Based on the accumulated evidence, *3DSD* activity and/or depletion of shikimate  
175 intermediates appear to be causing the main fitness burden when expressing the VG pathway in yeast  
176 (Figures 1C-D and 2). For this reason, we sequenced the genomically integrated *3DSD* gene of 22  
177 isolated single colonies from the fourth transfer of six parallel sequential batch cultures. From the  
178 sequencing analysis, we observed 7 premature stop codons, 5 SNPs, and 8 recombination events  
179 between the *3DSD* gene and either the gene encoding EntD or hsOMT, all controlled by the same  
180 *TEF1* promoter design and *CYCI* terminator (Figure 1B). The remaining 2 colonies sequenced did  
181 not have any mutations in the *3DSD* gene (Table 1).

182 Taken together, these results suggest that the fitness-burdened parental VG producing strain  
183 is genetically unstable, and that the burden exerted by the pathway is predominantly alleviated via  
184 mutations in the first enzymatic step of the pathway encoded by *3DSD*, converting 3DHS into PAC.  
185 Moreover, the single knockout experiment shows that loss of any subsequent VG pathway gene in a  
186 strain with an intact *3DSD* gene negatively impacts the growth rate of the resulting truncated pathway  
187 designs (Figure 1B).

188

## 189 **Biosensor candidates and characterization**

190 As already mentioned, control of population heterogeneity and stabilization of heterologous  
191 end-product formation has previously been established in bacteria by the use of small-molecule

192 biosensors (Rugbjerg et al., 2018b; Xiao et al., 2016). In this study we wished to extend from this  
193 concept and assess the potential for control of production from heterologous pathways in eukaryotes  
194 making use of control circuits founded on prokaryotic small-molecule biosensors conditionally  
195 controlling expression of native genes essential to yeast. Moreover, we aimed to explore the hitherto  
196 unknown potential of engineering control circuits for stabilizing pathway intermediates instead of  
197 end product formation, thereby aiming to demonstrate the use of many more small-molecule  
198 biosensors for control circuit applications than possible if only considering biosensor-assisted control  
199 of end product formation.

200 For choice of biosensors we selected VanR from *Caulobacter crescentus* and PcaQ from  
201 *Sinorhizobium meliloti*, which we recently designed and applied as biosensors for VAC and PAC,  
202 respectively (Ambri et al., 2020; D'Ambrosio et al., 2020). Importantly, engineering control circuits  
203 by the use of either VanR or PcaQ, would enable testing of circuit performance founded on two  
204 different modes-of-action, potentially impacting the stability of the control circuits. Mechanistically,  
205 VanR is a transcriptional repressor which, in the absence of VAC, prevents transcription by binding  
206 to VanR operator sites (VanO) in promoters and thus confers sterical hindrance of RNA polymerase  
207 activity (Gitzinger et al., 2012). In the presence of VAC, VanR undergoes a conformational change,  
208 decreasing its affinity to VanO, upon which transcription can start (Jain, 2015). For the PAC  
209 biosensor, the transcriptional activator PcaQ, a LysR-type transcriptional regulator, constitutively  
210 binds PcaO operator sites in gene promoters and induces transcription of the output gene in the  
211 presence of PAC (Ambri et al., 2020; Fernandez-López et al., 2015). Regarding the design of the  
212 genetically-encoded biosensors, the VAC biosensor is composed of a bi-directional system where  
213 VanR is expressed under the control of the constitutive *PGK1* promoter while the output gene is  
214 controlled by a synthetic VanO-containing *TEF1* promoter (Ambri et al., 2020). The strong promoter  
215 controlling the expression of GFP allows for a high maximum ON state, while simultaneously, a  
216 strong expression of the allosterically regulated transcription factor allows for a strong repression and  
217 therefore a low OFF state. This design supports an operational range spanning >2 orders of  
218 magnitude of VAC concentrations, including the range of metabolite concentration observed in the  
219 parental VG strain (Figure 2, and Supplementary Figure S4). For the PAC biosensor, PcaQ is  
220 expressed from the strong constitutive *TDH3* promoter, while the output gene is controlled by a  
221 truncated PcaO-containing *CYCI* promoter (209 bp). This design allow for a very low expression,  
222 and therefore leakiness, in the in the absence of PAC, and a high dynamic output range when PAC  
223 is produced intracellularly. (Ambri et al., 2020).



224 To characterize VanR and PcaQ biosensors for sensing VAC and PAC concentrations,  
225 respectively, we first introduced VanR or PcaQ together with either GFP-expressing VanO- or PcaO-  
226 containing reporter promoters in both the VG production strain as well as in the non-producing VG-  
227 3DSDΔ strain, and measured fluorescence outputs. Here, the introduction of VanR and PcaQ in the  
228 VG strain resulted in increases in GFP read-outs of 2.7- and 3.5-fold, respectively, compared to their  
229 expression in the VG-3DSDΔ strain (Figure 3), confirming that the biosensors are able to discriminate  
230 between VG-producing and non-producing strains.

231

### 232 **Evaluation of control circuit designs**

233 Spontaneous mutants with disruptive mutations in the *3DSD* gene, and therefore without the  
234 ability to produce VG and its biosynthetic intermediates, have a growth advantage compared to the  
235 strains harbouring the full VG pathway (Figure 1C-D). Eventually, such differences in growth rate  
236 and lag phase will allow for complete population take-over of non-producer cells during prolonged  
237 cultivations. To extend the productive life-span of a parental VG strain, we next sought to make use  
238 of the validated VAC and PAC biosensors for engineering control circuits in which mutants losing  
239 productivity will be subject to reduced fitness or even complete growth retardation. To do so, we  
240 decided to couple the expression of essential genes to the presence of VG pathway metabolites PAC  
241 and VAC, similar to previously reported studies in *E. coli* (Rugbjerg et al., 2018b; Xiao et al., 2016).  
242 Ideally, for such control circuits, only strains carrying a functional product pathway would be able to  
243 conditionally induce transcription of essential genes to a level sufficient for growth.

244 To select essential genes for control circuit designs, we performed a systematic analysis of  
245 candidate essential genes in yeast. From the total list of 5,188 validated open reading frames of the  
246 *S. cerevisiae* genome (Figure 4A)(Cherry et al., 2012), we initially selected four main classes of  
247 biosynthetic reactions (aiming to limit growth) that are not part of central carbon metabolism, namely  
248 1) nucleotide metabolism, 2) cofactor/vitamin metabolism, 3) lipid metabolism, and 4) amino acid  
249 metabolism, containing a total of 325 unique genes (Figure 4A, Supplementary Table S5). This list  
250 was further refined to focus on 3-4 selected metabolic pathways from each of the four classes (e.g.  
251 cysteine biosynthesis from homocysteine) totalling 110 unique genes, of which we omitted metabolic  
252 reactions catalysed by multiple gene products (e.g. *ADE5/ADE7*), bringing the gene list to 68  
253 candidates (Figure 4A). Of special attention, it should be noted that for selection of genes involved  
254 in amino acid biosynthesis, we initially made a complete list of the abundance of amino acids in the  
255 heterologous proteins of the VG pathway and compared this to the average amino acid composition

256 of yeast biomass (Lange and Heijnen, 2001). For example, glutamine accounts for only 3.98% of the  
257 amino acids in the VG pathway, whereas leucine is the most abundant accounting for 10.71%  
258 (Supplementary Table S6). For comparison, the same analysis for the average composition of yeast  
259 biomass, revealed that glutamine accounts for 7.75% of yeast biomass, and leucine for 8.03%  
260 (Supplementary Table S6), from which we hypothesized that a possible limitation in glutamine  
261 biosynthesis could effectively limit growth while having minimal impact on VG productivity. Finally,  
262 we decided to include *ARO2* as a candidate gene since it is involved downstream of the shikimate  
263 pathway (Gottardi et al., 2017), and for which limited expression could therefore help to accumulate  
264 more shikimate intermediate and thus boost VG pathway flux. To further refine the selection criteria  
265 to an operational number for control circuit testing, we focused our attention on 56 genes described  
266 as essential or causing auxotrophy (Cherry et al., 2012), and then only selected genes with an average  
267 expression level higher than the estimated VanO-containing *TEF1* promoter in the absence of VAC  
268 (*TEF1\_OFF*) across a wide range of yeast growth rates (i.e. 0.02-0.33 h<sup>-1</sup>) in glucose-limited aerobic  
269 chemostats (Regenberg et al., 2006). The *TEF1\_OFF* expression level was estimated by comparing  
270 the fluorescence intensity of the vanillic acid biosensor system in the absence of the inducer to the  
271 native *TEF1* promoter (Supplementary Figure S5). We then estimated the *TEF1\_ON* value based on  
272 the biosensor dynamic range (Supplementary Figure S4). Because of the low OFF state and dynamic  
273 range previously reported for the PcaQ biosensor design (Ambri et al., 2020), essential gene  
274 candidates with average expression within the VanR dynamic output range were also considered  
275 relevant for PAC control circuits founded on PcaQ. Finally, from this list of 34 genes, we manually  
276 selected 10 genes, where either accumulation or depletion of its respective substrate and product due  
277 to altered expression levels would not cause toxic effects (e.g. increased mutagenesis), as our  
278 candidate list of essential genes for control circuit testing (Figure 4A-B).

279 To test the performance of the control circuits, we initially introduced the VanR biosensor  
280 design in a prototrophic CEN.PK113-7D background strain by individually replacing the genomic  
281 locus, containing the first 150bp upstream of the first ATG of each of the 10 selected essential genes,  
282 with the synthetic construct (Supplementary Figure S6A). A similar approach was adopted for PAC  
283 control circuits, with the exception that PcaQ and the synthetic PcaO-containing *CYCI* promoter were  
284 introduced into both the parental VG producing strain and the non-productive VG-3DSD $\Delta$  strains  
285 (Supplementary Figure S6B). Following successful CRISPR-mediated promoter replacements, the  
286 strains were tested for conditional or improved growth upon external feeding of VAC or internal

287 formation of PAC in VG-producing strains compared to VG-3DSDA strains for the VAC and PAC  
288 control circuits, respectively.

289 For strains expressing the VAC control circuits, cells were grown in SM for 24 hours, then  
290 diluted into fresh medium in the presence or absence of VAC, and growth was subsequently  
291 monitored for 72 hours. From this, it was evident that when coupled to the glutamine synthase  
292 encoded by *GLN1*, the VAC control circuit enabled shortening of the initial lag phase by approx. 10  
293 hours in the presence of VAC, while the specific growth rate was not significantly altered between  
294 the different conditions (Figure 4C, Supplementary Figure S7). For the other 9 tested genes no VAC-  
295 dependent growth effects were observed.

296 Next, we assessed the growth when PcaQ was used to control the expression of the same set  
297 of 10 essential genes expressed from the PcaO-containing truncated *CYCI* promoter (Figure 4D,  
298 Supplementary Figure S8). Here, with the exception of *OLE1* and *CYS3*, and to a lesser extent also  
299 *URA2*, all control circuits had completely abolished growth of non-producing VG-3DSDA strains  
300 compared to VG-producing strains over 72 hours of cultivation (Figure 4D).

301 Taken together, this demonstrates that metabolic pathways involved in four different  
302 metabolic functions can be used for designing control circuits, and suggests that the low OFF state  
303 supported by the PcaO-containing truncated *CYCI* enables a broader range of essential genes  
304 covering a larger basal expression amplitude to be used, compared to control circuits founded on the  
305 repressor-type transcriptional regulator VanR controlling the synthetic VanO-containing *TEFI*  
306 promoter.

307

### 308 **Production stability of strains expressing control circuits**

309 By design, control circuits founded on genetically-encoded biosensors controlling the  
310 expression of essential genes may themselves be pressure points for fitness-burdened cells to escape  
311 heterologous anabolic product formation. In order to investigate the ability of the engineered control  
312 circuits for stably maintaining product formation over long cultivation regimes, we next introduced  
313 the VAC and PAC control circuit in the VG production strain, and repeated the batch cultivation  
314 experiment with seven sequential passages, spanning a total of approx. 55 generations (Figure 2A).  
315 Again, after each transfer the extracellular concentration of metabolites was assessed by HPLC.

316 As determined by HPLC analysis, the parental VG strain maintained its productive lifespan  
317 for VG and all VG-pathway intermediates for one passage following the selective preculture (approx.  
318 14 generations), yet with a >91% loss in VG productivity following four batch transfers, and a 98.4%

319 loss of VG productivity by the end of the sequential passage experiment (Figure 2C, Figure 5A). In  
320 comparison, for the strains armed with VAC control circuits one culture showed a gradual decrease  
321 in VG productivity, yet maintaining approx. 70% VG productivity at the end of the experiment (0.73  
322 mM to 0.52 mM VG), whereas the second culture had completely lost VG production by the end of  
323 the experiment (Figure 5B), indicating that the fitness-burdened VG producing strain can still escape  
324 the VAC control circuit and/or mutate *3DSD*.

325 For strains expressing the PAC control circuit, we repeatedly observed >50% decrease in  
326 PAC and VG productivity from the selective preculture to transfer 1 (Figure 5C). Yet following the  
327 first transfer, productivity increased immediately during the following batch cultivations, ending the  
328 passage experiment with an increase in VG productivity of 54.5% and 72.2% for the two biological  
329 replicates, respectively (Figure 5C). Furthermore, all the VG intermediates, with the exception of  
330 PAL, were produced at higher concentrations by the end of the passage experiment. More precisely,  
331 both biological replicates presented an approx. 30% increase in PAC levels and approximately twice  
332 as much VAN compared to the first transfer. However, the biggest increase was observed for VAC  
333 where the two biological replicates increased productivity by 188% and 137%, respectively (Figure  
334 5C).

335 Taken together, this time-resolved experiment demonstrates that control circuits coupling  
336 essential *GLNI* expression with accumulation of VAC and PAC, founded on the VanR transcriptional  
337 repressor and the transcriptional activator PcaQ, respectively, can enable extension of the productive  
338 lifespan of VG pathway, and in the case of PAC control circuit both pathway intermediates and final  
339 VG product formation is increased when compared to the non-stabilised VG strain.

340

### 341 **Population-level sequencing to assess integrity of control circuits**

342 Based on the results obtained from the batch cultivations of cells with and without control  
343 circuits (Figure 2, Figure 5), we next sought to determine whether i) the VanR-based control circuit  
344 mutated together with the VG pathway, and ii) if the cells expressing the PcaQ-based control circuits  
345 included mutations required to restore the growth rate and product formation following the first  
346 transfer (Figure 5). For this purpose, we whole-genome sequenced populations following the fourth  
347 and the seventh sequential culture for strains carrying the VanR-based control circuit and the third  
348 and the seventh culture for the strains with the PcaQ-based control of *GLNI* expression and we  
349 compared the results with their corresponding parental strains.

350 We mapped the whole-genome sequencing reads against the CEN.PK113-7D genome as a  
351 reference to assess genome coverage, base-calling and mutations. First, for the cultivation of the  
352 strains expressing the VAC control circuit, the replicate maintaining approx. 70% VG productivity  
353 following transfer 4 had no mutations identified, yet at transfer 7, a mutation localized in the VanO-  
354 containing *TEF1* promoter, driving the expression of the *3DSD* gene, was identified (Figure 6A).  
355 This mutation was observed in 23% of the reads from this population, and localized 18 bases  
356 downstream of the transcription start site of the *TEF1* promoter (Figure 6A). Moreover, in this  
357 replicate culture, two additional nonsynonymous mutations, encoding Q91P and P208S, were  
358 identified in 13% and 15% of the reads, respectively (Supplementary figure S9A-B). For the second  
359 replicate culture expressing the VAC control circuit, with a complete loss of VG productivity by the  
360 end of the cultivation, a single non-synonymous mutation in *3DSD*, encoding P208R, was observed  
361 in 63% of the reads by the end of the fourth culture (Figure 6B). Furthermore, approx. 40% of the  
362 reads showed a targeted 30 bp deletion in the *TEF1* promoter exactly covering the VanO sequence  
363 (Figure 6C). For the same replicate, at transfer 7 where no VG production was observed (Figure 5B),  
364 the P208R mutation in the coding region of the *3DSD* gene was present in 98% of the reads, and reads  
365 carrying the VanO site deletion increased to approx. 65% of the total population (Figure 6B-C).  
366 Finally, from the whole-genome sequence analysis of the PcaQ-stabilized strains no mutations were  
367 observed in the *3DSD* gene or the PcaQ biosensor design (Supplementary Figure S10).

368 Taken together, these results show that, at population level, both the VAC control circuit and  
369 *3DSD* are mutated for yeast to escape fitness-burdened VG production. Furthermore, for the strains  
370 expressing the VAC control circuit, these results suggest that the *3DSD* gene is likely to mutate before  
371 the synthetic *TEF1* promoter controlling the expression of the *GLN1* gene. On the contrary, strains  
372 expressing the PAC control circuit, founded on the transcriptional activator PcaQ and the minimalized  
373 synthetic *CYCI* promoter, enables robust expansion of the productive lifespan of the VG pathway,  
374 without any observed genetic perturbations.

375

### 376 **Laboratory-scale fed-batch process**

377 Based on the successful application of the control circuits for coupling VG pathway stability  
378 to essential glutamine biosynthesis via the *GLN1* gene during sequential shake flask experiments, we  
379 tested the VAC and PAC control circuit designs in a fed-batch process in order to test the control  
380 circuit under conditions often applied in industry. First, to mimic the preceding seed train, we grew  
381 pre-cultures of strains with and without the VAC or PAC control circuit under non-selective

382 conditions in rich medium. Following 24 hours, the pre-cultures were used to inoculate the first seed-  
383 train culture in a culture tube with a 1:100 inoculation ratio. Following another 48 hours, 40  $\mu\text{L}$  of  
384 this first seed-train culture was transferred to a 4-mL shake flask culture, and after another 48 hours  
385 this culture was used to inoculate a 400-mL bioreactor. This seed train from 40  $\mu\text{L}$  to 400 mL  
386 represents the same number of generations encountered in industrial seed trains starting from 1L and  
387 ending at 10,000 L (Fu et al., 2014).

388 The bioreactor culture started with a batch phase using 20 g/L of glucose and after carbon  
389 depletion, indicated by a rapid rise in dissolved oxygen levels and drop of off-gas  $\text{CO}_2$ , the fed-batch  
390 phase was started (Figure 7, and Supplementary Figure S11A-C). During the fed-batch, a  
391 concentrated solution of feed medium was used, and the growth rate was set to  $0.05\text{h}^{-1}$   
392 (Supplementary Table S7). Samples were taken at defined time-points (0, 20, 25, 44, 50, 68, 74 and  
393 92 hours) during the batch and fed-batch phases, and metabolite consumption and formation was  
394 determined off-line via HPLC analysis (Figure 7, Supplementary Figure S12). The cultures were  
395 stopped when the working volume in the bioreactor reached 900 mL. For the parental VG strain, the  
396 batch phase stopped after 40 hours, during which approx. 1.4 mmol of VG pathway metabolites were  
397 formed from the initial 20 g/L of glucose (Figure 7). Similarly, the batch phase of the strain expressing  
398 VAC control circuit terminated after 40 hours, yet with 1.9 mmol of VG pathway metabolites  
399 accumulated (Figure 7). In contrast, the strain expressing the PAC control circuit grew slower, and  
400 the batch phase only finished after 55 hours, during which approx. 1.3 mmol VG pathway metabolites  
401 accumulated (Figure 7). These results are in agreement with the observed drop in productivity of the  
402 parental VG strain after the second transfer in the sequential batch culture experiment (Figure 2B),  
403 suggesting that a fraction of parental VG producing cells in the inoculum of the bioreactor already  
404 exhibited loss of productivity. Following the initial batch phase, the impact of the control circuits  
405 became even more apparent in the fed-batch phase. Here, the strain expressing the PAC control circuit  
406 outperformed both the parental VG strain and the strain expressing the VAC control circuit by  
407 producing 11 mmol of VG pathway metabolites compared to approx. 2.2 mmol and 8.9 mmol of VG  
408 pathway metabolites for the VG and VAC control circuit strains, respectively (Figure 7). Importantly,  
409 even though the strains expressing control circuits accumulate 4-5-fold higher amounts of total VG  
410 pathway metabolites compared to the parental VG strain, these strains also accumulate higher  
411 amounts of the VG end-product. Indeed, for the strains expressing the VAC and PAC control circuits,  
412 at the end of the fermentation, a total of 2.34 mmol and 2.61 mmol of VG, respectively, is produced,  
413 compared to 1.36 mmol of VG produced by the parental VG strain, representing up to almost 2-fold

414 improvement in production (Figure 7). However, for the strains expressing the control circuits, there  
415 is also a substantial increase in the accumulation of VG pathway intermediates. For instance, and as  
416 also expected for control circuits founded on a PAC biosensor, in the strain expressing the PAC  
417 control circuit 6.8 mmol of PAC is accumulated, which is approx. 15 times the amount produced by  
418 the parental VG strain, and ~40% more compared to the VAC control circuit strain. Likewise, the  
419 strain expressing the VAC control circuit accumulates more VAC (1.5 mmol) than both the parental  
420 VG strain and the PAC control circuit strain (0.3 mmol and 0.5 mmol, respectively) (Figure 7).  
421 Furthermore, in the parental VG strains PAC accumulates until the measurement at 50 hours,  
422 following which the PAC levels drastically decrease, corroborating the findings from the batch  
423 cultivations (Figure 2). Similarly, PAL, which is almost entirely converted to VAN in the parental  
424 VG strains, accumulates to 0.14 and 1.05 mmol at the end of the cultivation in the strains expressing  
425 the VAC and PAC control circuit, while for VAN the parental VG strain accumulate 0.02 mmol  
426 compared to 0.05 and 0.09 mmol for the strains expressing the VAC and PAC control circuits,  
427 respectively (Figure 7).

428 In summary, the mimic of an industrial scale-up process, validates the use of control circuits  
429 founded on biosensors for biosynthetic pathway intermediates coupled to expression of essential  
430 genes, to prolong and improve the productive lifespan of yeast cell factories for anabolic end-product  
431 formation. Having said this, it is evident that PAC accumulated to relative high levels. Here it should  
432 be noted that in batch cultures, VG producing strains have been described to first grow respiro-  
433 fermentative, producing ethanol and predominantly PAC, and only when glucose is depleted, switch  
434 to fully respiratory growth on ethanol from which predominantly VG is formed (Strucko et al. 2015).  
435 In our study, the carbon/glucose-limited fed-batch was indeed operated below the growth rate at  
436 which *S. cerevisiae* switches to respiro-fermentative growth (Chen and Nielsen 2019), which thus  
437 could explain the relatively high levels of PAC.

438

## 439 **Discussion**

440 Engineering microorganisms to produce valuable chemicals and fuels has the potential to  
441 enable the transition towards a greener and more sustainable bio-based economy (Nielsen and  
442 Keasling, 2016). However, the metabolic burden caused by engineering heterologous pathways for  
443 anabolic product formation in cell factories is often associated with reduced fitness and growth rate  
444 (Strucko et al., 2015; Wu et al., 2016). This ultimately imposes a selective pressure on engineered

445 cells to reroute nutrients away from burdening non-essential pathways, or to delete these pathways  
446 completely, towards maximising cell proliferation (Rugbjerg et al., 2018a, 2018b).

447         Based on the result of the sequential shake flasks experiments we determined that strains  
448 expressing control circuits outperformed the parental strain without a control circuit, as strains  
449 expressing control circuits enabled strains to remain productive for >55 generations in batch  
450 cultivations, compared to merely 25 generations observed for the parental strain (Figure 2, Figure 5).  
451 Moreover, comparing the performance of these strains in a fed-batch cultivation mimicking industrial  
452 setups, strains expressing control circuits accumulated up to 5-fold higher amounts of total pathway  
453 metabolites, including up to 2-fold higher end-product formation for VAC and PAC control circuits,  
454 respectively. This demonstrates that biosensors derived from prokaryotic small-molecule binding  
455 transcriptional regulators, can be successfully employed in yeast to expand the productive lifespan  
456 and control evolutionary drift of fitness-burdened cell factories, even when coupling essential gene  
457 expression with formation of product pathway intermediates.

458         Moreover, this study highlights how physiological, genetic, and bioinformatic approaches  
459 enable the engineering of control circuits founded on pathway intermediates. Specifically, by  
460 constructing single knockout gene deletions for all heterologous pathway steps, we were able to  
461 identify the key fitness-burdening pressure point in strains expressing the VG pathway. Next, by  
462 mining publicly available transcriptome and phenome datasets (Cherry et al., 2012; Regenberget al.,  
463 2006), this study demonstrates successful selection criteria for identification of candidate essential  
464 genes, encoding a broad array of metabolic functions, which can be coupled to biosensors and thus  
465 enable selective growth based on small-molecule concentrations. With the increasing number of  
466 biosensors being developed, and demonstrations of fermentation-based manufacturing of valuable  
467 chemicals based on anabolic metabolism (Koch et al., 2019; Nielsen and Keasling, 2016), this  
468 combined approach should be applicable for stabilizing and optimizing many more bioprocesses in  
469 the future. Specifically, in this study, the stability of a fitness-burdened yeast cell factory was  
470 characterised and compared with strains expressing two different control circuit designs, capable of  
471 detecting pathway intermediates, coupled to essential gene expression. By focusing on biosensing of  
472 intermediates, our goal was to provide experimental guidelines to assess whether already established  
473 biosensors for pathway intermediates could be employed to successfully extend the productivity  
474 lifespan of a strain, without the need to engineer new biosensors for specific end-products. Moreover,  
475 by developing detecting intermediates it should be possible to re-use the same biosensor design to



476 stabilise the production of other pathways relying on the same intermediate, such as biosynthesis of  
477 *cis,cis*-muconic acid (Weber et al., 2012),

478         Having said this, this study not only exemplifies the error-modes of a fitness-burdening  
479 heterologous biosynthetic pathway, but also elucidates those observed in genetically-encoded control  
480 circuits, as those adopted in this study. First, by employing both transcriptional activators and  
481 repressors we observed that the PcaQ activator allowed for a wider range of essential genes to be used  
482 (Figure 4). Here, when replacing the native promoters with the PcaO-containing minimal *CYCI*  
483 promoter controlled by PcaQ, most of the tested essential genes were only able to sustain growth in  
484 strains producing PAC. On the contrary, when VanR was employed, all tested genes, with the  
485 exception of *GLNI*, showed similar growth upon VAC supplementation compared to control  
486 conditions. This is likely due to the lower OFF state of essential gene expression provided by the  
487 PAC control circuit founded on the minimal PcaO-containing *CYCI* promoter, highlighting the  
488 importance of biosensor output tuning when coupled to growth-based selection. Moreover, since  
489 many repressor-type biosensors established in *S. cerevisiae* rely on reporters with strong promoters  
490 to provide a readable output (Ambri et al., 2020; Dabirian et al., 2019; David et al., 2016; Hector and  
491 Mertens, 2017), this issue is believed to be a common concern for future strain stability efforts  
492 employing transcriptional repressors. Indeed, even though both types of control circuits lead to an  
493 increase in transcription in the presence of the ligand, inactivating mutations in the control circuits  
494 will lead to different outcomes depending on the aTF mode-of-action (D'Ambrosio and Jensen,  
495 2017). With a repressor-based control circuit, any mutation limiting DNA-binding affinity will lock  
496 the expression of the actuating gene (e.g. an essential gene) in a quasi-ON state, just as deletion of  
497 non-native aTF repressor binding sites in output promoter is likely to do (Ambri et al., 2020). This  
498 quasi-ON state indeed proved to be sufficient for *GLNI* in this study (Figure 5B and Figure 6C).  
499 Contrastingly, if an activator-type aTF is mutated, the system will be locked in an OFF state,  
500 maintaining non-producing cells in a low-fitness stage. Thus, we recommend designs of control  
501 circuits based on short sequence-diverse synthetic promoters (Kotopka and Smolke, 2019; Redden  
502 and Alper, 2015) and activator-type aTFs to limit the rapid spreading of simple error-modes towards  
503 quasi-ON expression of output genes or homologous recombination events as observed for the  
504 “sniper-attack” on 30 bp VanO in the *TEF1*-based output promoter (Figure 6C).

505         Still, with meticulous characterization of the error-modes of cell factories and the input-output  
506 relationship connecting aTF biosensors with essential metabolic functions, control circuits are  
507 transforming biosensors from mere high-throughput screening technologies into an integral part of

508 stabilizing bioprocesses, as already exemplified for bacterial cell factories (Rugbjerg et al., 2018b;  
509 Wang and Dunlop, 2019; Xiao et al., 2016). Ultimately, this will also enable understanding of the  
510 underlying mechanisms controlling population heterogeneity, and significantly contribute to  
511 development of new robust and cost-effective bio-based production processes, including long-term  
512 performance (500-1000 generations) making biomass reuse an option and reducing the need for seed  
513 trains. Beyond metabolic engineering, the engineering of control circuits also should hold potential  
514 for successful applications within other disciplines, including advanced microbiome therapeutics.

515

## 516 **Methods**

517

### 518 *Cultivation media and conditions*

519 Chemically competent *Escherichia coli* DH5 $\alpha$  strain was used as a host for cloning and plasmid  
520 propagation. The cells were cultivated at 37°C in 2xYT supplemented with 100  $\mu$ g/mL ampicillin.  
521 The *Saccharomyces cerevisiae* strains used in this study were grown at 30°C and 250 rpm in three  
522 types of media: yeast extract peptone (YP) medium (10 g/L Bacto yeast extract and 10 g/L Bacto  
523 peptone), synthetic complete (SC) medium (6.7 g/L yeast nitrogen base without amino acids with  
524 appropriate drop-out medium supplement) and synthetic medium (SM) prepared as previously  
525 described (Mans et al., 2018). All three media were supplemented with glucose 20 g/L as carbon  
526 source unless otherwise specified. For media preparation, salts and water were sterilised in the  
527 autoclave at 120°C, before the complete mixed media were sterile filtered with 0.2  $\mu$ m filters.

528

### 529 *Plasmids and strains construction*

530 All plasmids used in this study were assembled by USER<sup>TM</sup> (uracil-specific excision reagent) cloning  
531 (New England Biolabs). Biobricks constituting promoters, genes and other genetic elements required  
532 to assemble the plasmids were amplified by PCR using PhusionU polymerase (Thermo Fisher  
533 Scientific). *S. cerevisiae* strains were constructed by the lithium acetate/single-stranded carrier  
534 DNA/PEG method previously described (Gietz and Schiestl, 2007). The complete list of strains and  
535 plasmids used in this study is provided in Supplementary Tables S1 and S2.

536

### 537 *HPLC detection of extracellular metabolites*

538 All metabolites of the vanillin  $\beta$ -glucoside pathway were analysed by HPLC using the Dionex  
539 Ultimate 3000 HPLC (Thermo Fisher Scientific), coupled with the Supelco Discovery HS F5-3 HPLC

540 column (150 x 2.1 mm x 3  $\mu$ m) (Sigma Aldrich). Mobile phase A consisted of 10 mM ammonium  
541 formate, pH 3 while mobile phase B consisted of acetonitrile. The elution profile was as follows: 5%  
542 of solvent B for 0.5 min and increased linearly to 60% B over 5 min. The gradient was increased to  
543 90% B over 0.5 min and kept at this condition for 2 min. Finally, returned to 5% B and equilibrated  
544 until 10 min. The flow rate was set at 0.7mL/minute while the column was held at 30°C and the  
545 metabolites were detected using the UV diode detector DAD-3000 Diode Array Detector set at 260,  
546 277, 304 and 210 nm. The samples were prepared as previously described (Strucko et al., 2017).  
547 Shortly, 1 mL of yeast culture and 1 mL of 96% ethanol were mixed. The solution was then  
548 centrifuged at 12000g for 2 minutes. The supernatant was then collected and stored at -20°C until it  
549 was measured on the HPLC.

550

#### 551 *Biosensor design and promoter replacement*

552 The bidirectional VanR design used to replace essential genes promoters is composed of the *ADHI*  
553 terminator, VanR from *Caulobacter crescentus*, the *PGKI* promoter driving the expression of VanR  
554 and the engineered TEF1p containing two VanO sequences separated by the Eco47III restriction site.  
555 The design as described was used to replace the 150bp sequence upstream of the selected essential  
556 genes. The PcaQ biosensor design is composed of two parts: PcaQ, under the control of the strong  
557 TDH3 promoter and the reporter module composed of the truncated CYC1 promoter containing the  
558 PcaQ binding site, both previously described (Ambri et al., 2020). The complete list of the gRNAs  
559 used in this study can be found in Supplementary Table S3. Each gRNA sequence was then combined  
560 with a backbone carrying the pRNR2-Cas9-CYC1t cassette to assemble an all-in-one CRISPR  
561 plasmid, by USER<sup>TM</sup> (uracil-specific excision reagent) cloning (New England Biolabs), as previously  
562 described (D'Ambrosio et al., 2020). In order to maximise the transformation efficiency the plasmid  
563 were used to transform yeast strains where one additional copy of TEF1p-Cas9-CYC1t was already  
564 present in the genome within the EasyClone site X-4 site (Jensen et al., 2014) .

565

#### 566 ~~*Growth profiler analysis*~~

#### 567 *Cell Growth assessment*

568 Cell growth was evaluated using the Growth Profiler 960 (EnzyScreen B.V., The Netherlands) at  
569 30°C and 200 rpm or the ELx808 Absorbance Microplate Reader (BioTek) at 30°C and “fast”  
570 shaking. Prior to Growth Profiler measurement, *S. cerevisiae* strains, with the exception of strains  
571 carrying the PcaQ biosensor design, were inoculated in 0.5 mL of synthetic medium in 96-format

572 polypropylene deep-well plates, and grown overnight at 30°C and 300 rpm. The cells were then  
573 diluted 1:100 in fresh synthetic medium. Because of the longer lag phase or inability to grow in SM  
574 medium (Supplementary Figure S8), the strains where the native essential gene promoter was  
575 replaced with the PcaQ biosensor design were initially inoculated in rich YPD medium and grown  
576 overnight. Next, the strains were diluted 1:10 in synthetic medium and cultured overnight. Finally,  
577 the strains were diluted 1:100 in fresh synthetic medium to a final volume of 150  $\mu$ L and the cell  
578 suspension was transferred to a 96-half deepwell plate (EnzyScreen B.V., The Netherlands). In order  
579 to convert the G-values provided by the instrument into OD<sub>600</sub> values we generated a calibration curve  
580 by measuring the G-value of samples with known OD. The strains measured by the ELx808 were  
581 cultivated in the same manner, and the OD<sub>630</sub> values were used to assess the growth.

582

#### 583 *Flow cytometry measurements*

584 Single cell fluorescence was evaluated using a Becton Dickinson LSR FORTESSA equipped with a  
585 blue 488 nm laser. Prior to measurement, *S. cerevisiae* strains were grown overnight in mineral  
586 medium at 30°C and 300 rpm in 96-format polypropylene deep-well plates. Next, the cells were  
587 diluted 1:50 in fresh mineral medium in the presence or absence of the inducer and were cultivated  
588 for 20 hours. Finally, cells were diluted 1:20 in PBS to arrest cell growth and the fluorescence was  
589 measured by flow cytometry. For each sample 10,000 single-cell events were recorded.

590

#### 591 *Whole genome sequencing*

592 The samples selected for whole genome sequence were inoculated from glycerol stock in rich YPD  
593 medium and cultured overnight. The genomic DNA was extracted by using the Quick-DNA  
594 Fungal/Bacterial Miniprep Kit (ZymoResearch) following the provided protocol. DNA libraries were  
595 then prepared using a Kapa Hyper Prep Library Prep Kit (Roche) and sequenced by Illumina MiSeq.  
596 Data mapping was performed against the CEN.PK113-7D genome (Salazar et al., 2017) where  
597 additional expression cassettes relative to vanillin- $\beta$ -glucoside biosynthetic pathway genes and  
598 control circuits were previously added. Data processing and chromosome copy number variation  
599 determinations were performed as previously described (Nijkamp et al., 2012; Verhoeven et al.,  
600 2017).

601

602

603

604 *Fed-batch cultivations*

605 The bioreactor cultures were performed in 1 L bioreactors (Biostat Q Plus, Sartorius, Gottingen,  
606 Germany) and started with a batch phase using 400 mL synthetic medium containing 20 g/L of  
607 glucose and 5 mL Antifoam 204 (Sigma A6426). The temperature was maintained at 30°C and the  
608 pH was kept constant at 5.0 by dropwise addition of a 10M KOH solution. The cultures were sparged  
609 with pressurized air at a flow rate of 500 mL/min and dissolved oxygen levels were maintained above  
610 50% by controlling the stirrer speed. The off-gas CO<sub>2</sub> and O<sub>2</sub> was monitored throughout the  
611 cultivation (Prima BT Mass Spectrometer, Thermo Fisher Scientific) and the data was acquired by  
612 the Lucullus software (Securecell AG, Switzerland). After carbon depletion, indicated by a rapid rise  
613 in dissolved oxygen levels, the fed-batch phase was automatically initiated (Supplementary Figure  
614 S9). During the fed-batch phase, a 2x concentrated SM solution containing 200 g/L glucose and  
615 Antifoam (1mL/L), was used. The initial feed rate was set to 2 mL h<sup>-1</sup>, resulting in a growth rate of  
616 0.05 h<sup>-1</sup> thus ensuring an identical length of the fed-batch cultivation for all the tested strains.  
617 Throughout the fed-batch phase, the feed rate was continuously increased with a rate of 0.05 h<sup>-1</sup> to  
618 maintain a constant growth rate. Samples were taken manually at defined time points during the batch  
619 and fed-batch phase and metabolite consumption and formation were determined via HPLC analysis.

620

621 **Acknowledgements**

622 This work was supported by the Novo Nordisk Foundation and by the European Union's Horizon  
623 2020 research and innovation programme under the Marie Skłodowska-Curie action PACMEN (grant  
624 agreement No. 722287). Finally, we would like to thank Dr. Tomas Strucko for sharing with us the  
625 parental *S. cerevisiae* VG strain used in this study.

626

627 **Author contributions**

628 RM, PR, MOAS, JDK and MKJ conceived the study. VD, ED, RDB and RM conducted all  
629 experimental work related to strain designs and construction, MvdB performed all next-generation  
630 sequencing analysis, while JtH and SS conducted all fermentation. VD, RM, and MKJ wrote the  
631 manuscript.

632

633 **Declaration of interests**

634 JDK has a financial interest in Amyris, Lygos, Demetrix, Maple Bio, and Napigen. PR has a  
635 financial interest in Enduro Genetics ApS. MOAS has financial interest in UNION therapeutics,

636 Biosyntia, Clinical-Microbiomics, UTILITY therapeutics and SNIPR holding.

637

## 638 **Figure legends**

639

### 640 **Figure 1. Identification of fitness-burdening reactions in the vanillin- $\beta$ -glucoside biosynthetic** 641 **pathway.**

642 (A) Schematic representation of the vanillin- $\beta$ -glucoside biosynthetic pathway and the enzymes  
643 involved in vanillin- $\beta$ -glucoside (VG) biosynthesis; 3DSD (3-dehydroshikimate dehydratase from  
644 *Podospora anserina*), hOMT (O-methyltransferase from *Homo sapiens*), ACAR (aromatic  
645 carboxylic acid reductase from *Nocardia iowensis*), EntD (phosphopantetheine transferase from  
646 *Escherichia coli*), UGT (UDP-glycosyltransferase from *Arabidopsis thaliana*). (B) Schematic  
647 representation of biosynthetic pathway integration in EasyClone sites within chromosome XII. (C)  
648 Growth profile of single knockout strains. Each curve is a representative of three (n=3) biological  
649 replicates. (D) Maximum specific growth rate observed over a 5-hours interval within the 67 hours  
650 cultivation. Single-knockout strains of genes of interest (GOI, indicated as VG-GOI $\Delta$ ) are compared  
651 to the strain expressing the complete VG pathway (VG-Full pathway). Each bar represents the  
652 average of three (n=3) biological replicates with error bars representing mean  $\pm$  standard deviation.  
653 Asterisks indicate statistical significance level as evaluated by t-test comparing growth rates for each  
654 of the different strains expressing a truncated pathway compared to the growth of the full VG pathway  
655 strain: NS =  $p > 0.5$ , \*\* =  $p \leq 0.01$ , \*\*\* =  $p \leq 0.001$ .

656

### 657 **Figure 2. Assessing vanillin- $\beta$ -glucoside biosynthetic pathway stability during prolonged** 658 **cultivation using metabolite profiling.** (A) Schematic layout of the sequential transfer regime of

659 batch cultures. The strains were initially cultivated in YPD overnight. Next, the cultures were diluted  
660 in synthetic medium to allow the strains to acclimate for continued growth in synthetic medium. (B)  
661 HPLC analysis of the extracellular metabolite concentrations for the VG strain following the first  
662 sequential passage. (C) Extracellular metabolite concentrations for the VG strain after 48 h  
663 cultivations over seven sequential transfers. The bars represent the average of two (n=2) biological  
664 replicates. Error bars represent mean  $\pm$  standard deviation from two (n=2) biological replicates.

665

666 **Figure 3. Biosensor design and *in vivo* validation.** (A) Schematic illustration of the conducted  
667 testing of PAC and VAC biosensors, PcaQ and VanR, respectively, in strain backgrounds with

668 complete (VG - Full pathway strain) or broken (VG-3DSD $\Delta$ ) pathway. **(B)** yeGFP fluorescence  
669 intensity presented as violin density plots for Mean fluorescence intensity (MFI) of VanR and PcaQ  
670 biosensor designs in the vanillin- $\beta$ -glucoside producing strains (VG-Full pathway) and non-  
671 producing (VG-3DSD $\Delta$ ) strains.

672

673 **Figure 4. Selection of essential genes and testing of VAC and PAC control circuits.** **(A)**  
674 Schematic illustration of the various filtering criteria applied for essential gene selection. The number  
675 of genes passing each of the seven filtering steps are indicated in the grey-coloured bars, and the steps  
676 filtering criteria indicated to the right. **(B)** Native expression levels of essential genes selected for  
677 promoter replacement. Genes were selected for different metabolic functions: nucleotide metabolism  
678 (yellow), fatty acid metabolism (black), amino acid metabolism (purple) and vitamin/cofactor  
679 metabolism (blue). **(C)** Growth profile of wild type CEN.PK strains carrying the VAC control circuit  
680 design in the presence (yellow) or absence (purple) of 2mM vanillic acid. **(D)** Growth profile of VG  
681 pathway strains (yellow) and VG-3DSD $\Delta$  strains (purple) carrying the PAC control circuit design.  
682 Each curve is representative of a minimum of two biological replicates. It was not possible to identify  
683 a colony having the *FAS1* promoter replaced by the PAC control circuit.

684

685 **Figure 5. Assessing vanillin- $\beta$ -glucoside biosynthetic pathway stability in biosensor control**  
686 **circuit strains.** **(A)** Extracellular metabolite concentrations for the VG strain after 48 h cultivations  
687 over seven sequential transfers (Insert from Figure 2C). **(B-C)** HPLC analysis of the extracellular  
688 metabolites for strains harboring control circuits based on VanR (A) or PcaQ (B) during serial passage  
689 experiments. For (B-C) each bar represents total accumulated extracellular metabolites of the VG  
690 biosynthetic pathway based on one (n=1) biological replicate. For (B-C) each bar represents one  
691 biological replicate.

692

693 **Figure 6. Whole-genome population level sequencing identifies the error-modes of VAC control**  
694 **circuits.** **(A-B)** Genome-viewer zooms on the *3DSD* gene of the two replicate VAC control circuit  
695 strains at transfer 4 and 7 (see also Figure 5A). The blue and orange bars represent the ratio of wild-  
696 type (blue) and mutated (orange) sequence reads aligned to *3DSD*. Below the bar plots for read  
697 coverage, the genomic layout of the *3DSD* gene expression unit is indicated with the *TEF1* presented  
698 in green and the *3DSD* gene in yellow. **(C)** Genome-viewer zoom on the synthetic VanO-containing  
699 *TEF1* promoter of the VAC control circuit strain (replicate 2, Figure 5A). The VanO operator site is

700 marked with a red box. Below the bar plot for read coverage, the genomic layout of the *GLNI* gene  
701 expression unit is indicated with the *TEF1-VanO* promoter presented in green and the *GLNI* gene in  
702 yellow. For (A-C) read coverage assembled to the CEN.PK113-7D reference genome is indicated to  
703 the right.

704

705 **Figure 7. Fed-batch bioprocess for parental VG strain and strains expressing VAC and PAC**  
706 **control circuits.** Extracellular metabolite and growth characterization of the parental VG strain (left  
707 panel), and strains expressing VAC (middle panel) and PAC (right panel) control circuits during the  
708 batch and fed-batch bioprocess. Metabolite production is expressed in mmol of VG pathway  
709 metabolites produced during the cultivation. The values were corrected for the volume of medium  
710 removed for HPLC sampling and represent one (n=1) biological replicate. Data for a second  
711 biological replicate can be found in Supplementary Figure S12. Dashed black lines represent off-gas  
712 CO<sub>2</sub> (percent), while black arrows represent the beginning of the fed-batch phase as inferred from  
713 initial increase in dissolved oxygen (see also Supplementary Figure S11). Coloured lines indicate  
714 accumulation of individual VG pathway metabolites during the cultivation (Time, h) according to  
715 colour coding indicated at the bottom of the plot.

716

717 **Table 1. List of identified mutations in the 3DSD gene.** List of the identified mutations in the *3DSD*  
718 gene at the end of the fourth sequential passage from six parallel cultivations. Each entry represents  
719 the result from one of the 22 sequenced colonies.

720

## 721 References

- 722 Ambri, F., D'Ambrosio, V., Di Blasi, R., Maury, J., Jacobsen, S.A.B., McCloskey, D., Jensen, M.K.,  
723 Keasling, J.D., 2020. High-Resolution Scanning of Optimal Biosensor Reporter Promoters in Yeast.  
724 ACS Synth. Biol. <https://doi.org/10.1021/acssynbio.9b00333>
- 725 Brochado, A.R., Matos, C., Møller, B.L., Hansen, J., Mortensen, U.H., Patil, K.R., 2010. Improved vanillin  
726 production in baker's yeast through in silico design. Microb. Cell Fact. 9, 84.  
727 <https://doi.org/10.1186/1475-2859-9-84>
- 728 Carlquist, M., Fernandes, R.L., Helmark, S., Heins, A.-L., Lundin, L., Sørensen, S.J., Gernaey, K.V., Lantz,  
729 A.E., 2012. Physiological heterogeneities in microbial populations and implications for physical stress  
730 tolerance. Microb. Cell Fact. 11, 94. <https://doi.org/10.1186/1475-2859-11-94>
- 731 Cherry, J.M., Hong, E.L., Amundsen, C., Balakrishnan, R., Binkley, G., Chan, E.T., Christie, K.R.,  
732 Costanzo, M.C., Dwight, S.S., Engel, S.R., Fisk, D.G., Hirschman, J.E., Hitz, B.C., Karra, K., Krieger,  
733 C.J., Miyasato, S.R., Nash, R.S., Park, J., Skrzypek, M.S., Simison, M., Weng, S., Wong, E.D., 2012.  
734 Saccharomyces Genome Database: the genomics resource of budding yeast. Nucleic Acids Res. 40,  
735 D700–5. <https://doi.org/10.1093/nar/gkr1029>
- 736 Dabirian, Y., Gonçalves Teixeira, P., Nielsen, J., Siewers, V., David, F., 2019. FadR-Based Biosensor-  
737 Assisted Screening for Genes Enhancing Fatty Acyl-CoA Pools in *Saccharomyces cerevisiae*. ACS



738 Synth. Biol. 8, 1788–1800. <https://doi.org/10.1021/acssynbio.9b00118>

739 D’Ambrosio, V., Jensen, M.K., 2017. Lighting up yeast cell factories by transcription factor-based  
740 biosensors. *FEMS Yeast Res.* 17. <https://doi.org/10.1093/femsyr/fox076>

741 D’Ambrosio, V., Pramanik, S., Goroncy, K., Jakociunas, T., Schönauer, D., Davari, M.D., Schwaneberg, U.,  
742 Keasling, J.D., Jensen, M.K., 2020. Directed evolution of VanR biosensor specificity in yeast.  
743 *Biotechnology Notes.* <https://doi.org/10.1016/j.biotno.2020.01.002>

744 David, F., Nielsen, J., Siewers, V., 2016. Flux Control at the Malonyl-CoA Node through Hierarchical  
745 Dynamic Pathway Regulation in *Saccharomyces cerevisiae*. *ACS Synth. Biol.* 5, 224–233.  
746 <https://doi.org/10.1021/acssynbio.5b00161>

747 Elowitz, M.B., Levine, A.J., Siggia, E.D., Swain, P.S., 2002. Stochastic gene expression in a single cell.  
748 *Science* 297, 1183–1186. <https://doi.org/10.1126/science.1070919>

749 Fazenda, M.L., Dias, J.M.L., Harvey, L.M., Nordon, A., Edrada-Ebel, R., Littlejohn, D., McNeil, B., 2013.  
750 Towards better understanding of an industrial cell factory: investigating the feasibility of real-time  
751 metabolic flux analysis in *Pichia pastoris*. *Microb. Cell Fact.* 12, 51. <https://doi.org/10.1186/1475-2859-12-51>

752

753 Fernandez-López, R., Ruiz, R., de la Cruz, F., Moncalián, G., 2015. Transcription factor-based biosensors  
754 enlightened by the analyte. *Front. Microbiol.* 6, 648. <https://doi.org/10.3389/fmicb.2015.00648>

755 Flachbart, L.K., Sokolowsky, S., Marienhagen, J., 2019. Displaced by Deceivers: Prevention of Biosensor  
756 Cross-Talk Is Pivotal for Successful Biosensor-Based High-Throughput Screening Campaigns. *ACS*  
757 *Synth. Biol.* 8, 1847–1857. <https://doi.org/10.1021/acssynbio.9b00149>

758 Fu, Z., Verderame, T.D., Leighton, J.M., Sampey, B.P., Appelbaum, E.R., Patel, P.S., Aon, J.C., 2014.  
759 Exometabolome analysis reveals hypoxia at the up-scaling of a *Saccharomyces cerevisiae* high-cell  
760 density fed-batch biopharmaceutical process. *Microb. Cell Fact.* 13, 32. <https://doi.org/10.1186/1475-2859-13-32>

761

762 Gietz, R.D., Schiestl, R.H., 2007. High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG  
763 method. *Nat. Protoc.* 2, 31–34. <https://doi.org/10.1038/nprot.2007.13>

764 Gitzinger, M., Kemmer, C., Fluri, D.A., El-Baba, M.D., Weber, W., Fussenegger, M., 2012. The food  
765 additive vanillic acid controls transgene expression in mammalian cells and mice. *Nucleic Acids Res.*  
766 40, e37. <https://doi.org/10.1093/nar/gkr1251>

767 Gomes, J., Chopda, V., Rathore, A.S., 2018. Monitoring and Control of Bioreactor: Basic Concepts and  
768 Recent Advances, in: Komives, C., Zhou, W. (Eds.), *Bioprocessing Technology for Production of*  
769 *Biopharmaceuticals and Bioproducts.* John Wiley & Sons, Inc., Hoboken, NJ, USA, pp. 201–237.  
770 <https://doi.org/10.1002/9781119378341.ch6>

771 Gottardi, M., Reifenrath, M., Boles, E., Tripp, J., 2017. Pathway engineering for the production of  
772 heterologous aromatic chemicals and their derivatives in *Saccharomyces cerevisiae*: bioconversion from  
773 glucose. *FEMS Yeast Res.* 17. <https://doi.org/10.1093/femsyr/fox035>

774 Gu, H., Zhu, Y., Peng, Y., Liang, X., Liu, X., Shao, L., Xu, Y., Xu, Z., Liu, R., Li, J., 2019. Physiological  
775 mechanism of improved tolerance of *Saccharomyces cerevisiae* to lignin-derived phenolic acids in  
776 lignocellulosic ethanol fermentation by short-term adaptation. *Biotechnol. Biofuels* 12, 268.  
777 <https://doi.org/10.1186/s13068-019-1610-9>

778 Guo, Z., Olsson, L., 2014. Physiological response of *Saccharomyces cerevisiae* to weak acids present in  
779 lignocellulosic hydrolysate. *FEMS Yeast Res.* 14, 1234–1248. <https://doi.org/10.1111/1567-1364.12221>

780 Hansen, E.H., Møller, B.L., Kock, G.R., Bünner, C.M., Kristensen, C., Jensen, O.R., Okkels, F.T., Olsen,  
781 C.E., Motawia, M.S., Hansen, J., 2009. De novo biosynthesis of vanillin in fission yeast  
782 (*Schizosaccharomyces pombe*) and baker’s yeast (*Saccharomyces cerevisiae*). *Appl. Environ.*  
783 *Microbiol.* 75, 2765–2774. <https://doi.org/10.1128/AEM.02681-08>

784 Hector, R.E., Mertens, J.A., 2017. A Synthetic Hybrid Promoter for Xylose-Regulated Control of Gene  
785 Expression in *Saccharomyces* Yeasts. *Mol. Biotechnol.* 59, 24–33. <https://doi.org/10.1007/s12033-016-9991-5>

786

787 Jain, D., 2015. Allosteric control of transcription in GntR family of transcription regulators: A structural  
788 overview. *IUBMB Life* 67, 556–563. <https://doi.org/10.1002/iub.1401>

789 Jensen, N.B., Strucko, T., Kildegaard, K.R., David, F., Maury, J., Mortensen, U.H., Forster, J., Nielsen, J.,  
790 Borodina, I., 2014. EasyClone: Method for iterative chromosomal integration of multiple genes in

791 *Saccharomyces cerevisiae*. FEMS Yeast Res. 14, 238–248. <https://doi.org/10.1111/1567-1364.12118>

792 Koch, M., Pandi, A., Borkowski, O., Batista, A.C., Faulon, J.-L., 2019. Custom-made transcriptional  
793 biosensors for metabolic engineering. Curr. Opin. Biotechnol. 59, 78–84.  
794 <https://doi.org/10.1016/j.copbio.2019.02.016>

795 Kotopka, B.J., Smolke, C.D., 2019. Model-driven generation of artificial yeast promoters. bioRxiv.  
796 <https://doi.org/10.1101/748616>

797 Kruyer, N.S., Peralta-Yahya, P., 2017. Metabolic engineering strategies to bio-adipic acid production. Curr.  
798 Opin. Biotechnol. 45, 136–143. <https://doi.org/10.1016/j.copbio.2017.03.006>

799 Lange, H.C., Heijnen, J.J., 2001. Statistical reconciliation of the elemental and molecular biomass  
800 composition of *Saccharomyces cerevisiae*. Biotechnol. Bioeng. 75, 334–344.  
801 <https://doi.org/10.1002/bit.10054>

802 Luziatelli, F., Brunetti, L., Ficca, A.G., Ruzzi, M., 2019. Maximizing the Efficiency of Vanillin Production  
803 by Biocatalyst Enhancement and Process Optimization. Front Bioeng Biotechnol 7, 279.  
804 <https://doi.org/10.3389/fbioe.2019.00279>

805 Mans, R., Wijsman, M., Daran-Lapujade, P., Daran, J.-M., 2018. A protocol for introduction of multiple  
806 genetic modifications in *Saccharomyces cerevisiae* using CRISPR/Cas9. FEMS Yeast Res. 18.  
807 <https://doi.org/10.1093/femsyr/foy063>

808 Müller, S., Harms, H., Bley, T., 2010. Origin and analysis of microbial population heterogeneity in  
809 bioprocesses. Curr. Opin. Biotechnol. 21, 100–113. <https://doi.org/10.1016/j.copbio.2010.01.002>

810 Nielsen, J., Keasling, J.D., 2016. Engineering Cellular Metabolism. Cell 164, 1185–1197.  
811 <https://doi.org/10.1016/j.cell.2016.02.004>

812 Nijkamp, J.F., van den Broek, M.A., Geertman, J.-M.A., Reinders, M.J.T., Daran, J.-M.G., de Ridder, D.,  
813 2012. De novo detection of copy number variation by co-assembly. Bioinformatics 28, 3195–3202.  
814 <https://doi.org/10.1093/bioinformatics/bts601>

815 Redden, H., Alper, H.S., 2015. The development and characterization of synthetic minimal yeast promoters.  
816 Nat. Commun. 6, 7810. <https://doi.org/10.1038/ncomms8810>

817 Regenberg, B., Grotkjaer, T., Winther, O., Fausbøll, A., Akesson, M., Bro, C., Hansen, L.K., Brunak, S.,  
818 Nielsen, J., 2006. Growth-rate regulated genes have profound impact on interpretation of transcriptome  
819 profiling in *Saccharomyces cerevisiae*. Genome Biol. 7, R107. [https://doi.org/10.1186/gb-2006-7-11-](https://doi.org/10.1186/gb-2006-7-11-r107)  
820 [r107](https://doi.org/10.1186/gb-2006-7-11-r107)

821 Rugbjerg, P., Myling-Petersen, N., Porse, A., Sarup-Lytzen, K., Sommer, M.O.A., 2018a. Diverse genetic  
822 error modes constrain large-scale bio-based production. Nat. Commun. 9, 787.  
823 <https://doi.org/10.1038/s41467-018-03232-w>

824 Rugbjerg, P., Sarup-Lytzen, K., Nagy, M., Sommer, M.O.A., 2018b. Synthetic addiction extends the  
825 productive life time of engineered *Escherichia coli* populations. Proc. Natl. Acad. Sci. U. S. A. 115,  
826 2347–2352. <https://doi.org/10.1073/pnas.1718622115>

827 Rugbjerg, P., Sommer, M.O.A., 2019. Overcoming genetic heterogeneity in industrial fermentations. Nat.  
828 Biotechnol. 37, 869–876. <https://doi.org/10.1038/s41587-019-0171-6>

829 Salazar, A.N., Gorter de Vries, A.R., van den Broek, M., Wijsman, M., de la Torre Cortés, P., Brickwedde,  
830 A., Brouwers, N., Daran, J.-M.G., Abeel, T., 2017. Nanopore sequencing enables near-complete de  
831 novo assembly of *Saccharomyces cerevisiae* reference strain CEN.PK113-7D. FEMS Yeast Res. 17.  
832 <https://doi.org/10.1093/femsyr/fox074>

833 Snoek, T., Romero-Suarez, D., Zhang, J., Ambri, F., Skjoedt, M.L., Sudarsan, S., Jensen, M.K., Keasling,  
834 J.D., 2018. An Orthogonal and pH-Tunable Sensor-Selector for Muconic Acid Biosynthesis in Yeast.  
835 ACS Synth. Biol. 7, 995–1003. <https://doi.org/10.1021/acssynbio.7b00439>

836 Strucko, T., Buron, L.D., Jarczynska, Z.D., Nødvig, C.S., Mølgaard, L., Halkier, B.A., Mortensen, U.H.,  
837 2017. CASCADE, a platform for controlled gene amplification for high, tunable and selection-free gene  
838 expression in yeast. Sci. Rep. 7, 41431. <https://doi.org/10.1038/srep41431>

839 Strucko, T., Magdenoska, O., Mortensen, U.H., 2015. Benchmarking two commonly used *Saccharomyces*  
840 *cerevisiae* strains for heterologous vanillin- $\beta$ -glucoside production. Metabolic Engineering  
841 Communications 2, 99–108. <https://doi.org/10.1016/j.meteno.2015.09.001>

842 Tao, R., Zhao, Y., Chu, H., Wang, A., Zhu, J., Chen, X., Zou, Y., Shi, M., Liu, R., Su, N., Du, J., Zhou, H.-  
843 M., Zhu, L., Qian, X., Liu, H., Loscalzo, J., Yang, Y., 2017. Genetically encoded fluorescent sensors

844 reveal dynamic regulation of NADPH metabolism. *Nat. Methods* 14, 720–728.  
845 <https://doi.org/10.1038/nmeth.4306>  
846 Verduyn, C., Postma, E., Scheffers, W.A., Van Dijken, J.P., 1992. Effect of benzoic acid on metabolic fluxes  
847 in yeasts: a continuous-culture study on the regulation of respiration and alcoholic fermentation. *Yeast*  
848 8, 501–517. <https://doi.org/10.1002/yea.320080703>  
849 Verhoeven, M.D., Lee, M., Kamoen, L., van den Broek, M., Janssen, D.B., Daran, J.-M.G., van Maris,  
850 A.J.A., Pronk, J.T., 2017. Mutations in PMR1 stimulate xylose isomerase activity and anaerobic growth  
851 on xylose of engineered *Saccharomyces cerevisiae* by influencing manganese homeostasis. *Sci. Rep.* 7,  
852 46155. <https://doi.org/10.1038/srep46155>  
853 Wang, T., Dunlop, M.J., 2019. Controlling and exploiting cell-to-cell variation in metabolic engineering.  
854 *Curr. Opin. Biotechnol.* 57, 10–16. <https://doi.org/10.1016/j.copbio.2018.08.013>  
855 Weber, C., Brückner, C., Weinreb, S., Lehr, C., Essl, C., Boles, E., 2012. Biosynthesis of cis,cis-muconic  
856 acid and its aromatic precursors, catechol and protocatechuic acid, from renewable feedstocks by  
857 *Saccharomyces cerevisiae*. *Appl. Environ. Microbiol.* 78, 8421–8430.  
858 <https://doi.org/10.1128/AEM.01983-12>  
859 Wu, G., Yan, Q., Jones, J.A., Tang, Y.J., Fong, S.S., Koffas, M.A.G., 2016. Metabolic Burden: Cornerstones  
860 in Synthetic Biology and Metabolic Engineering Applications. *Trends Biotechnol.* 34, 652–664.  
861 <https://doi.org/10.1016/j.tibtech.2016.02.010>  
862 Xiao, Y., Bowen, C.H., Liu, D., Zhang, F., 2016. Exploiting nongenetic cell-to-cell variation for enhanced  
863 biosynthesis. *Nat. Chem. Biol.* 12, 339–344. <https://doi.org/10.1038/nchembio.2046>  
864 Zhang, J., Sonnenschein, N., Pihl, T.P.B., Pedersen, K.R., Jensen, M.K., Keasling, J.D., 2016. Engineering  
865 an NADPH/NADP<sup>+</sup> Redox Biosensor in Yeast. *ACS Synth. Biol.* 5, 1546–1556.  
866 <https://doi.org/10.1021/acssynbio.6b00135>

867

868